A Study of the Safety and Pharmacokinetics of CNTO 136 in Patients With Cutaneous Lupus Erythematosus and Systemic Lupus Erythematosus
Phase 1
Completed
- Conditions
- Lupus Erythematosus, CutaneousLupus Erythematosus, Systemic
- Interventions
- Drug: 1 mg/kg CNTO 136Drug: 4 mg/kg CNTO 136Drug: 10 mg/kg CNTO 136Drug: Placebo
- First Posted Date
- 2012-10-08
- Last Posted Date
- 2012-10-08
- Lead Sponsor
- Centocor Research & Development, Inc.
- Target Recruit Count
- 49
- Registration Number
- NCT01702740
A Study of the Safety and Efficacy of Single-agent Carlumab (an Anti-Chemokine Ligand 2 [CCL2]) in Participants With Metastatic Castrate-Resistant Prostate Cancer
- First Posted Date
- 2009-10-09
- Last Posted Date
- 2013-06-24
- Lead Sponsor
- Centocor Research & Development, Inc.
- Target Recruit Count
- 46
- Registration Number
- NCT00992186
A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Psoriasis
Phase 3
Completed
- Conditions
- Psoriasis
- Interventions
- Drug: Ustekinumab (CNTO 1275) 45 mgDrug: Placebo; Ustekinumab (CNTO 1275) 45 or 90 mgDrug: Ustekinumab (CNTO 1275) 90 mg
- First Posted Date
- 2006-03-28
- Last Posted Date
- 2013-01-24
- Lead Sponsor
- Centocor Research & Development, Inc.
- Target Recruit Count
- 1230
- Registration Number
- NCT00307437
A Study of Safety and Effectiveness of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Plaque-type Psoriasis
- First Posted Date
- 2005-12-22
- Last Posted Date
- 2013-06-17
- Lead Sponsor
- Centocor Research & Development, Inc.
- Target Recruit Count
- 766
- Registration Number
- NCT00267969
© Copyright 2025. All Rights Reserved by MedPath